Commitments and Contingencies (Details) ₪ in Thousands |
1 Months Ended | 3 Months Ended | 9 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|---|
|
Jun. 23, 2022
USD ($)
|
Aug. 31, 2021
USD ($)
|
Aug. 31, 2021
ILS (₪)
|
Mar. 31, 2021 |
Mar. 31, 2022
USD ($)
|
Mar. 31, 2022
ILS (₪)
|
Sep. 30, 2022
USD ($)
|
Sep. 30, 2022
ILS (₪)
|
Oct. 31, 2019
USD ($)
|
|
| Commitments and Contingencies (Details) [Line Items] | |||||||||
| Approvement, description | A.In March 2021, the IIA approved two new applications in relation to the Company’s cystic fibrosis product candidate for an aggregate budget of NIS 10,879 (approximately $3,286) and for the Company’s product candidate for Inflammatory Bowel Disease (“IBD”) and Primary Sclerosing Cholangitis for an aggregate budget of NIS 8,565 (approximately $2,588). | ||||||||
| Percentage of total fund | 30.00% | 30.00% | |||||||
| Received amount of programs (in New Shekels) | ₪ | ₪ 577 | ||||||||
| Received amount | $ 395,000 | 1,365 | |||||||
| Aggregate budget | $ 1,778,000 | ₪ 5,737 | $ 4,094,000 | ₪ 13,004 | |||||
| Total approved grants | 8,403,000 | ₪ 28,683 | |||||||
| Total grants received | 6,957,000 | ||||||||
| Total grants subject to royalties | 6,380,000 | ||||||||
| Total contingent obligation | $ 6,557,000 | ||||||||
| Received fees | $ 1,411 | ||||||||
| Collaboration agreement, description | The fees will be paid in instalments of $500 within 30 days of the Effective Date and three additional installments of $500, $200 and $211 upon completion of certain activities under the research plan. Unless terminated earlier, this agreement will remain in effect until (a) a period of eighteen (18) months thereafter or (b) completion of the project plan and submission and approval of the final report, whichever occurs sooner, unless otherwise extended. The consideration is recorded as a reduction of R&D expenses, net in the condensed consolidated statements of operations according to the input model method on a cost-to-cost basis. The remainder of the consideration is recorded as other accounts payable in the condensed consolidated balance sheets. During the nine months ended September 30, 2022, the Company received consideration of $500 and recorded $230 in the condensed consolidated statements of operations. | ||||||||
| Loan agreement amount | $ 19,000 | ||||||||
| Minimum [Member] | |||||||||
| Commitments and Contingencies (Details) [Line Items] | |||||||||
| Percentage of total fund | 30.00% | 30.00% | |||||||
| Royalties rate | 3.00% | 3.00% | |||||||
| Maximum [Member] | |||||||||
| Commitments and Contingencies (Details) [Line Items] | |||||||||
| Percentage of total fund | 50.00% | 50.00% | |||||||
| Royalties rate | 3.50% | 3.50% | |||||||
| BiomX Israel [Member] | |||||||||
| Commitments and Contingencies (Details) [Line Items] | |||||||||
| Received amount of programs (in New Shekels) | ₪ | ₪ 4,284 | ||||||||
| Received amount | $ 1,347,000 | ||||||||